rs4570625 — TPH2 G-703T

Promoter variant affecting brain serotonin synthesis enzyme; influences emotional reactivity, anxiety, and depression risk

See your personal result for TPH2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Brain's Serotonin Factory Switch

TPH2 (tryptophan hydroxylase 2) is the rate-limiting enzyme11 rate-limiting enzyme
The slowest step in a biochemical pathway, which determines the overall speed of production for serotonin synthesis in the brain. Unlike its cousin TPH1, which makes serotonin in the gut and other peripheral tissues, TPH2 works exclusively in neurons—particularly in the raphe nuclei22 raphe nuclei
Clusters of serotonin-producing neurons in the brainstem that project throughout the brain, regulating mood, sleep, and emotional processing of the midbrain. The rs4570625 variant sits 703 base pairs upstream of the TPH2 gene's start site, in a regulatory region that controls how much enzyme gets made.

The Mechanism

This G>T substitution affects a promoter region where transcription factors33 transcription factors
Proteins that bind to DNA and control gene expression by turning genes on or off bind to initiate TPH2 gene expression. In vitro studies suggest the T allele is associated with reduced TPH2 promoter activity, potentially lowering serotonin synthesis capacity. Brain imaging studies have found that carriers of different alleles show altered reactivity in the amygdala44 amygdala
The brain's emotional processing center, especially for fear and threat detection and ventromedial prefrontal cortex55 ventromedial prefrontal cortex
Brain region involved in emotional regulation, decision-making, and inhibiting negative emotions during emotional tasks.

The Evidence

The most comprehensive evidence comes from a 2012 meta-analysis of 27 studies including 13,041 cases and 11,568 controls, which found rs4570625 significantly associated with major depressive disorder (summary OR = 0.83, 95% CI: 0.73–0.96) . However, the direction of risk has been contentious.

A 2017 Estonian population study found that TT homozygous males reported less aggressive behavior, lower scores on maladaptive impulsivity, fewer ADHD symptoms, and lower rates of anxiety disorders compared to G-allele carriers .

Yet other research points in the opposite direction.

A 2023 pharmacological fMRI study found that specifically GG carriers experienced anxiogenic effects during acute tryptophan depletion (which transiently lowers serotonin), while TT carriers did not .

The G-allele has been suggested to relate to hypofunction of tryptophan hydroxylase and lower serotonin synthesis rates , though the functional implications remain incompletely understood.

The clearest pattern emerges when considering gene-environment interactions66 gene-environment interactions
When genetic variants influence how a person responds to environmental factors like stress, creating different outcomes than either factor alone.

Single marker analyses showed significant gene-by-environment interactions with rs4570625 on depressive symptoms .

An interaction between TPH2 rs4570625 and BDNF Val66Met yields two at-risk groups for difficulty inhibiting negative emotional content: BDNF Val/Val combined with TPH2 G/G, and BDNF Met carriers combined with TPH2 T allele .

Practical Implications

Because the functional effects of this variant depend heavily on genetic background and environmental context, the practical guidance is less about the variant itself and more about understanding your vulnerability patterns. If you're a GG carrier, you may be more susceptible to mood changes when serotonin synthesis is temporarily compromised—for example, during periods of high stress, poor sleep, or low dietary tryptophan intake. TT carriers appear more resilient to transient serotonin fluctuations but may have other vulnerabilities depending on interactions with variants in genes like BDNF.

The key actionable insight is that serotonin synthesis depends on adequate tryptophan (the dietary precursor), cofactors like vitamin B677 vitamin B6
Required for the enzyme that converts 5-hydroxytryptophan to serotonin, and iron (required for TPH2 enzyme function). Unlike some genetic variants where supplementation directly addresses the problem, TPH2 variants don't create a specific nutrient deficiency—they affect the efficiency of the enzyme that uses those nutrients.

Interactions

The most well-documented interaction is with BDNF rs6265 (Val66Met). The combination of BDNF genotype and TPH2 rs4570625 genotype creates distinct emotional regulation profiles that neither variant predicts alone. Specifically, BDNF Val/Val + TPH2 GG shows impaired negative emotion inhibition, as does BDNF Met + TPH2 T-carrier status, suggesting epistasis88 epistasis
When the effect of one gene variant depends on the presence of another gene variant between these serotonergic and neurotrophic pathways.

Within the TPH2 gene itself, rs4570625 is in linkage disequilibrium99 linkage disequilibrium
When variants are inherited together more often than would be expected by chance, forming haplotype blocks with rs11178997, rs1386494, and rs7305115, forming haplotypes that collectively influence TPH2 expression and psychiatric risk more than any single variant.

For those interested in understanding their broader serotonergic genetics, variants in SLC6A4 (serotonin transporter), HTR1A and HTR2A (serotonin receptors), and MAOA (serotonin degradation) interact with TPH2 to shape overall serotonergic tone and psychiatric vulnerability.

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal

Potentially enhanced emotional resilience and lower baseline anxiety

The TT genotype has been associated with favorable emotional and behavioral outcomes in several population studies. A large Estonian study found that TT males reported significantly less aggressive behavior across multiple measures (Life History of Aggression interview, Illinois Bully Scale), lower maladaptive impulsivity, fewer teacher-rated ADHD symptoms, and lower rates of anxiety disorders by young adulthood. A Mexican population study found TT carriers had lower stress and depression scores and better psychological quality of life.

Perhaps most compellingly, a pharmacological challenge study found that TT carriers were resistant to the anxiety-inducing effects of acute tryptophan depletion, while GG carriers experienced significant increases in subjective anxiety and alterations in brain threat processing. This suggests that the TT genotype may confer resilience to fluctuations in serotonin availability.

The mechanism is not entirely clear. Some in vitro data suggest the T allele may be associated with higher TPH2 expression compared to the G allele, which would provide greater capacity for serotonin synthesis. However, other studies have found mixed results, and the relationship between this promoter variant and actual TPH2 enzyme levels in human brain tissue remains incompletely characterized.

It's important to note that having a "protective" genotype does not confer immunity to depression or anxiety—these are complex multifactorial conditions influenced by dozens of genetic variants, life experiences, current stressors, and other biological factors. The TT genotype appears to be one factor that shifts the probability distribution slightly toward better emotional regulation, but it's far from deterministic.

GT Intermediate

Intermediate serotonin synthesis regulation with moderate stress sensitivity

Heterozygotes express both alleles, with the overall TPH2 expression presumably falling between that of GG and TT homozygotes. The codominant inheritance pattern means that both alleles contribute to your phenotype, rather than one dominating. In practice, this means you're likely somewhere in the middle of the distribution for TPH2 activity and serotonin synthesis capacity.

Research on heterozygotes specifically is limited, as most studies compare homozygous groups to maximize statistical power. However, the pattern across studies suggests that GT carriers show intermediate responses to serotonergic challenges and intermediate levels of stress-related psychiatric symptoms compared to GG and TT homozygotes.

Your risk profile likely depends heavily on genetic and environmental context—particularly other serotonergic variants, BDNF genotype, early life stress exposure, and current environmental stressors. The moderate effect size of this variant means that for most heterozygotes, it represents one small piece of a complex genetic and environmental puzzle influencing mood regulation.

GG Sensitive

Baseline serotonin synthesis capacity with potential vulnerability to transient disruptions

The G allele at position -703 in the TPH2 promoter has been associated with altered emotional regulation in several neuroimaging and pharmacological studies. A 2023 fMRI study using acute tryptophan depletion (which temporarily lowers serotonin by removing its dietary precursor) found that GG carriers experienced increased subjective anxiety and reduced ventromedial prefrontal cortex activity in response to threat-related stimuli, while TT carriers were protected. This suggests that when serotonin synthesis capacity is challenged, GG carriers may be at greater risk for emotional dysregulation.

The mechanism likely involves subtle differences in TPH2 expression levels. In vitro studies suggest the G-703 variant may be associated with slightly lower TPH2 promoter activity compared to the T allele, though this finding has not been entirely consistent across studies. Lower TPH2 expression would theoretically mean less capacity for serotonin synthesis, particularly under conditions of high demand.

The meta-analysis data showing the G allele associated with increased depression risk must be interpreted cautiously, as effect sizes are small (OR ~1.2) and heavily context-dependent. The clearest evidence is that GG genotype interacts with environmental stressors and other genetic variants (particularly BDNF Val66Met) to influence emotional processing and psychiatric risk.